- Joined
- Nov 10, 2023
- Messages
- 88
Mike Israetel is presenting information that was published February 2024. The subjects in that study were monkeys, not humans, and the results yielded a lot of muscle growth and retention in a caloric deficit.
In a phase I trial with humans after 26 weeks, the results are not nearly as impressive as they were in the monkey study.
Here is a data table from the monkey study:
There were 4 groups.
Group 1 - No drug intervention
Group 2 - Semaglutide only
Group 3 - Semaglutide + myostatin inhibitor
Group 4 - Semaglutide + myostatin inhibitor + activin-A
Group 1 saw fat loss and some muscle loss. Group 2 saw more fat loss but also more muscle loss. Group 3 saw even more fat loss but less muscle loss. Group 4 saw significant muscle loss but some muscle GAIN. This was the study on monkeys.
Here are data tables from the 26 week study on humans:
The groups were
Group 1 - semaglutide only
Group 2 - semaglutide + low dose myostatin inhibitor
Group 3 - semaglutide + higher dose myostatin inhibitor
Group 4 - semaglutide + high dose myostatin inhibitor + activin-A
Group 1 saw average 15lbs fat loss and 8lbs muscle loss.
Group 2 saw average 17lbs fat loss and 4lbs muscle loss.
Group 3 saw average 19lbs fat loss and 4lbs muscle loss.
Group 4 saw average 25lbs fat loss and 2lbs muslce loss.
Unlike the monkey study, there was no muscle gained as far the data shows. The rate of fat loss increased significantly alongside the rate of muscle retention.
Unless we test these therapies in a caloric surplus, it is unknown at what rate they will affect rate of gain of muscle:fat (P ratio), especially with other compounds in use (anabolics, growth hormone, insulin, etc.).
In the human trial, in group 4 (Sema+mi+actA), 2 of 147 patients passed away. Both suffered cardiac events. In all the groups in the human study, ~28% subjects dropped out due to severe side effects. Studies linked below.
Monkey study data on page 20:
Human trial published June 2025 -
www.globenewswire.com
In a phase I trial with humans after 26 weeks, the results are not nearly as impressive as they were in the monkey study.
Here is a data table from the monkey study:

There were 4 groups.
Group 1 - No drug intervention
Group 2 - Semaglutide only
Group 3 - Semaglutide + myostatin inhibitor
Group 4 - Semaglutide + myostatin inhibitor + activin-A
Group 1 saw fat loss and some muscle loss. Group 2 saw more fat loss but also more muscle loss. Group 3 saw even more fat loss but less muscle loss. Group 4 saw significant muscle loss but some muscle GAIN. This was the study on monkeys.
Here are data tables from the 26 week study on humans:


The groups were
Group 1 - semaglutide only
Group 2 - semaglutide + low dose myostatin inhibitor
Group 3 - semaglutide + higher dose myostatin inhibitor
Group 4 - semaglutide + high dose myostatin inhibitor + activin-A
Group 1 saw average 15lbs fat loss and 8lbs muscle loss.
Group 2 saw average 17lbs fat loss and 4lbs muscle loss.
Group 3 saw average 19lbs fat loss and 4lbs muscle loss.
Group 4 saw average 25lbs fat loss and 2lbs muslce loss.
Unlike the monkey study, there was no muscle gained as far the data shows. The rate of fat loss increased significantly alongside the rate of muscle retention.
Unless we test these therapies in a caloric surplus, it is unknown at what rate they will affect rate of gain of muscle:fat (P ratio), especially with other compounds in use (anabolics, growth hormone, insulin, etc.).
In the human trial, in group 4 (Sema+mi+actA), 2 of 147 patients passed away. Both suffered cardiac events. In all the groups in the human study, ~28% subjects dropped out due to severe side effects. Studies linked below.
Monkey study data on page 20:
Human trial published June 2025 -
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving...